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ABSTRACT 
Betsy Crosswhite, Dr. Ziaeddin Shariat-Madar 
University of Mississippi Pharmacy School, Dept. Biomolecular Sciences, University, 
MS 38677 
 
 This study investigated natural product inhibitors of blood coagulation Factor XII 
(FXII). FXII initiates the Kallikrein Kinin-System (KKS) within the intrinsic coagulation 
pathway. Increased expression of this system leads to proinflammatory and procoagulant 
activities. Inflammation occurs through downstream activation in the KKS. Following the 
activation of FXII-dependent pathway, bradykinin (BK) binds to the BK receptor 2 (B2) 
and produces inflammatory signaling. Abnormally increased BK can result in life 
threatening Hereditary Angioedema (HAE), characterized by severe reoccurring swelling. 
FXII is critical for pathogenic thrombosis, but is dispensable for hemostasis. This unique 
property of FXII makes it an attractive drug target. We hypothesized that the 
identification of a specific inhibitor for activated FXII could lead to the reduction of 
Hereditary Angioedema Type III (HAE III) symptoms and hinder thrombosis formation 
without an increased risk for bleeding. In this study, we presented an extension of our 
previous work, which dealt with high-throughput screening of plant extracts and a large 
compound collections to target FXIIa. We identified myricitin as a candidate compound 
via a systemic experimental screening.  Chromogenic activated FXII activity assays were 
preformed to test the effects of myricitrin analogues on plasma enzymes (FXIIa, FXIa, 
and kallikrein). To assess the inhibitory effects of candidate compounds on these 
proteases, the release of paranitrianalide from the chromogenic substrates were measured 
 vi 
as indicator of FXIIa, FXIa, or kallikrein activity. The results of this study showed that 
myricetin, an analogue of myricitrin, significantly inhibited FXIIa at the sub-micromolar 
to the low micromolar concentration range. Overall, myricetin has the potential to be a 
useful multifunctional therapeutic drug in patients with HAE and thrombolytic diseases.  
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INTRODUCTION 
1.1 Factor XII-Driven Plasma Contact System  
Fibrin formation functions through two pathways: extrinsically through tissue 
damage or intrinsically initiated by Factor XII (FXII). The Kallikrein Kinin-System 
functions within the intrinsic coagulation pathway supporting proinflammatory and 
procoagulant activities1.  
The multifunctional FXII initiates the coagulation pathway2. FXII is released by 
the liver and mapped on the human chromosome number 53. It is divided into two 
regions, one heavy chain and one light chain. The heavy chain is divided into three 
distinct regions. The first region has a molecular weight of 40,000, can bind to 
negatively charged surfaces and does not detect enzymatic activity4. The second  has 
a molecular weight of 28,000, cannot participate in artificial surface binding4. Similar 
to the first heavy chain region, the third can securely bind to negatively charged 
surfaces, with a molecular weight of 12,0004. FXII activation occurs either by auto 
activation by contact with a negative surface (solid-phase activation), or by adding a 
protease that leads to enzymatic cleavage (fluid-phase activation)5.  
Zymogen FXII goes through a conformational change to its activated enzymatic 
form, FXIIa, following contact with a negatively charged surface6. Local activators 
include platelet polyphosphates, mast cell-derived heparin, collagen1, and systemic 
initiators such as: glycated proteins, microparticles, and activated endothelium1. 
FXIIa cleaves prekallikrein (PK) which subsequently forms kallikrein7. Activated PK 
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can reciprocally activate FXII and induce a positive feedback loop for FXII 
activation7 (Diagram 1). Kallikrein cleaves high molecular weight kininogen (HK) 
which results in the liberation of bradykinin (BK). BK then binds to the kinin B2 
receptor (B2R) which activates proinflammatory signaling pathways8. The Kallikrein 
Kinin-System affects coagulation, vascular permeability through inflammation and 
edema, blood pressure, glucose homeostasis, adipogenesis, and wound healing9 
(Diagram 2). 
 
 
 
 
 
Diagram 1: The Mechanism of Activation behind coagulation Factor XII.   
Lynch J, Shariat-Madar Z (2012) Physiological Effects of the Plasma Kallikrein-Kinin 
System: Roles of the Blood Coagulation Factor XII (Hageman Factor). J Clinic Toxicol 
2:e105.  
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Diagram 2: The Kallikrein-Kinin system can be activated both locally and 
systemically by FXII. Feener, E. P.; Zhou, Q.; Fickweiler, W. Role of Plasma Kallikrein 
in Diabetes and Metabolism. Thromb. Haemost. 2013, 110 (3), 434–441. 
 
 
 
1.2.1 Functions of FXII: Inflammation 
BK is an essential mediator for inflammation. The main producer of BK is the 
plasma contact system in which FXII is the activator. Within the KKS, the binding 
of BK to the B2 receptor (Diagram 1) leads to inflammation. This results in dilated 
vessels, increased vascular permeability, and the induction of chemotaxis in 
neutrophils1. When tissue becomes injured or infected, local increases in vascular 
permeability and controlled inflammation are critical for repair and protection10. 
Closely related to FXII and its inflammatory properties is Hereditary angioedema 
(HAE). HAE consists of reoccurring severe swelling specifically in the arms, legs, 
face, and airway. For patients with Type I and Type II HAE there is a deficiency in 
C1-esterase inhibitor (C1INH). FXIIa activates the fibrinolytic system through PK 
urokinase activation1. The main inhibitor for FXIIa and PK is serpin C1 esterase 
 4 
inhibitor that functions within the contact activation system. Contrastingly, in Type 
III HAE C1INH functions properly and yet patients still suffer from angioedema. 
Type III HAE has been shown to be an autosomal dominant disease stemming from 
a missense, gain of function, mutation on the FXII gene11. A deficiency of FXII can 
result in  thrombo-protection , but excess FXII activity corresponds with HAE with 
an abundance in BK formation12.  The Madar lab has carried out previous studies to 
generate an inhibitor of activated FXIIa in order to reduce overexpression of BK.  
 
1.2.2 Functions of FXII: Thrombosis 
Venous thromboembolism (VTE) occurs when a blood clot forms, often in 
deep veins of the legs (Deep Vein Thrombosis). This condition becomes life 
threatening when the blood clot breaks free from the venous wall and potentially 
travels to the lungs, resulting in a Pulmonary Embolism (PE). FXIIa induces 
fibrin formation through FXI in the intrinsic coagulation pathway12. This 
contributes to VTE, deep vein thrombosis, PE, ischemic stroke, and 
atherothrombosis12.  A major cause of death in the Western world, 
atherothrombosis, produces thrombus formation within blood vessels. The 
buildup of lipid material within vessel walls can ultimately manifest into coronary 
artery disease and stroke. Impairing FXII- dependent fibrin formation in ischemic 
tissue produces thrombo-protective effects1. This makes drug targets for FXII an 
attractive mechanism to effectively protect against pathogenic thrombosis without 
an increased risk of hemorrhage that is a side effect for current anticoagulant 
drugs13. 
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A prolonged activated partial thromboplastin time (aPTT) tests the speed 
of clotting. If the clotting takes more than 70 seconds, the aPTT test results show 
spontaneous bleeding. Interestingly, patients with a FXII deficiency show a 
prolonged aPTT test but are asymptomatic for bleeding.  
The role of FXII in thrombotic disease remains controversial. Some 
anecdotal evidence, including patient zero, Mr. Hageman, suggest a FXII 
deficiency increases thrombotic risk factors. In contrast, clinical studies did not 
find an association with FXII deficiency and thromboembolic disease14. While 
this is true, the overall lack of controlled FXII data cannot confirm the presence of 
thromboprotection in the presence of a FXII deficiency.  
When a blood vessel is injured, blood platelets are activated as well as the 
plasma coagulation system. This induces fibrin formation  which produce a blood 
clot together with platelets. Experiments with the Ross Bengal/laser of vascular 
injury models and FeCl3 showed an acute deficiency for thrombus formation in 
FXII-deficient mice8. This challenged the previously accepted coagulation 
balance1. FXII is critical for “pathogenic” thrombosis, but it does not play a role 
in the “physiologic” hemostatic fibrin formation at the site of injury1. Also 
controversial is FXII’s role in thrombotic disease. Isolated human trials did not 
find an association between FXII deficiency and thromboembolic disease15, even 
though data supports FXII’s role in thrombosis in mice models16. Alternatively, 
epidemiology studies show support for FXII and FXIIa in relation to arterial 
thrombosis16.  The intrinsic coagulation system shows activation with increased 
risk for coronary heart disease16. In patients with ischemic heart disease, studies 
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show elevated levels of FXII in systemic circulation17. Experimental stroke 
models using FXII deficient mice exhibit protection from cerebral ischemia18. 
This makes drug targets for FXII an attractive mechanism to effectively protect 
against pathogenic thrombosis without an increased risk of hemorrhage that is a 
side effect for current anticoagulant drugs8. 
 
1.2.3 Functions of FXII: No Role in Hemostasis  
The intrinsic pathway of FXII driven plasma contact system offers 
promising insight for new research3. FXII promotes the possibility for an 
anticoagulant target of thrombosis without impacting hemostasis1. FXII’s in vitro 
role in the plasma contact system is well known, but this enzyme’s role in an in 
vivo setting is still largely unclear. Despite its contribution to fibrin formation in 
vitro, FXII-initiated coagulation in vivo was not considered to be significant1. In 
animal and human models a FXII deficiency does not result in a clinically 
relevant bleeding phenotype, thus people with FXII deficiency, severe or partial, 
do not suffer excessive bleeding from the site of injury19,20. The inconsistency 
with FXII’s in vitro and in vivo activity is currently unknown and requires further 
investigation.   
Like FXII deficiency, people with inadequate PK or HK do not suffer 
hemostasis.  Both of these deficiencies are commonly diagnosed during a 
screening of the activated partial thromboplastin time (aPTT)1. In contrast, 
patients who are deficient in FXI suffer from hemophilia C which is a mild 
bleeding disorder initiated by trauma. Additionally, hemophilia A is caused by a 
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lack of FVIII, and hemophilia B’s source is a tissue factor (TF) deficiency. These 
observed tendencies suggest that fibrin formation takes place through the extrinsic 
coagulation pathway21. This is confirmed by FVIIa/TF- driven coagulation by the 
“revised model of coagulation”. This model demonstrates that FXI can activate 
FXIIa during clotting, independent of FXII21.  While FXII is dispensable for fibrin 
formation in hemostasis, future studies are recommended due to the rarity of 
severe deficiencies22. 
 
1.3.1 Kallikrein: Significance of a Physiological Inhibitor 
Plasma kallikrein is a serine protease that cleave peptide bonds and is a 
key enzyme in the KKS. It functions within this pathway as a combined unit of 
PK and HK. HK has a molecular weight of 115,000 and combined with PK 
weighs 285,00023. PK and HK are associated with a noncovalent bond and act 
jointly upon FXIIa activation23. Plasma Kallikrein liberates BK which participates 
in blood pressure regulation and inflammation activation. Clinically, kallikrein is 
a drug target for HAE and is a biomarker for multiple types of cancer24. 
Additionally, plasma kallikrein has been found to be an activator for pro-
urokinase which then transforms into its active form, urokinase. This is important 
in fibrinolysis within the FXII dependent intrinsic pathway1. 
 
1.3.2 FXII: Significance of a Physiological Inhibitor  
FXII is a plasma protein within the intrinsic coagulation pathway. It is also known 
as the Hageman factor due to its discovery in the first case study. FXII has a 
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molecular weight of 76,000 daltons and consists of a 596 amino acid glycoprotein1.  
FXII is the zymogen form of the protease. Once activated by a negatively charged 
surface, it becomes FXIIa, a serine protease enzyme. FXIIa participates in the 
initiation of coagulation, BK production, and fibrinolysis25.  Within the KKS, FXIIa 
activates PK to kallikrein. Then alpha FXII, a form of FXII, causes the activation of 
FXI in conjunction with HK which participates in thrombosis independent of FXII3. 
Mice deficient in the B2 receptor and FXII show a reduced risk for arterial 
thrombosis26. This suggests a proteolytic system that can reduce arterial thrombosis 
without affecting hemostasis. Moreover, the KKS can be activated dependent and 
independent of FXII26. 
Currently, drugs targeting blood clotting increase the risk for bleeding. Heparin is 
a known anticoagulant administered intravenously for venous thrombosis and 
arterial coagulation. Additionally, Warfarin is an oral anticoagulant with a high 
affinity for binding plasma proteins. Drawbacks for known inhibitors of the intrinsic 
coagulation system are slow onset and lack of FXII specificity27. The risks 
associated with these drugs provides a basis for an improved anticoagulation target 
that does not increase bleeding.  
 
1.4 History of the Hageman Factor   
Fibrin formation functions through two pathways. The extrinsic pathway is 
initiated by exposure to a damaged blood vessel wall1.  In contrast, the intrinsic 
pathway responds to blood-borne factors1.  The intrinsic pathway relies on the 
Hageman factor, FXII, for initiation.  The history of this protease dates back to John 
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Hageman28.  He died as a result of pulmonary embolism following a pelvic.  After 
fracturing his left hemipelvis, he was put on bed rest and subsequently allowed to 
walk.  Just days later, Hageman lost a pulse and the ability to breathe which lead to 
an immediate death.  Investigation into his passing revealed a large blood clot 
impeding flow through both left and right pulmonary arteries as well as multiple 
thrombi from veins in his lower extremities28. Hageman serves as the index patient 
for FXII deficiency.  
 
1.5   Summary  
A FXII inhibitor has the potential to be an effective anticoagulant drug without 
affecting hemostasis. The plasma KKS offers a promising research opportunity for 
therapeutic applications relating to inflammatory thrombolytic diseases3. For this 
study, we hypothesized that the identification of a specific inhibitor for activated 
FXII could lead to the reduction of HAE III symptoms and hinder thrombosis 
formation without an increased risk for bleeding. 
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RESULTS AND DISCUSSION 
2.1 Enzyme Kinetic Determination  
 Figures 1, 2 and 3 display the optimal physiological concentrations of FXIIa, 
FXIa and CS-31(02), respectively. The resulting concentrations were then used in all 
experiments quantifying the inhibition of FXIIa, FXIa and Kallikrein by natural product 
compounds. The outcome from the chromogenic assays preformed indicated that a final 
concentration of 9 nM FXIIa (Figure 1) successfully hydrolyzed CS-32(02) without 
oversaturating the absorbance detectors. These experiments were repeated three times 
and supported by data from other publications. The data from Figure 2 demonstrated that 
an 18 nM concentration of FXIa should be used in the presence of S2366 for all further 
experiments. The Km measures a substrate’s ability to interact with an enzyme. Thus, the 
Km  range for CS-31(02) was determined to be 0.44 to 0.59 mM in the presence of FXIIa 
(Figure 3). The data also confirmed a 0.43 mM final concentration for CS-31(02) to be 
used in measurements for FXIIa activity.  
 
 
 
 
 
 
 11 
FXIIa Concentration Response
[FXIIa] (nM)
S
2
3
0
2
 H
y
d
ro
ly
s
is
(O
D
 4
0
5
 n
m
)
0 2 4 6 8 10
0.0
0.2
0.4
0.6
0.8
1.0
 
Figure 1: Enzyme Kinetic Determination of FXIIa. FXIIa activity was assayed to 
determine a consistent concentration of FXIIa to use in the presence of CS-31(02). Due to 
this experiment, 9 nM FXIIa was used in subsequent experiments to measure changes in 
FXIIa activity. Two independent experiments were conducted to generate this data. Each 
experiment consisted of three independent replicates. Mean ± SEM. 
 
Figure 2: Enzyme Kinetic Determination of FXIa. FXIa activity was assayed to 
determine a consistent concentration of FXIa to use in the presence of S2366. Due to this 
experiment, 18 nM FXIa was used in subsequent experiments to measure changes in 
FXIa activity. One independent study was used for this data. Each experiment consisted 
of three independent replicates. Mean ± SEM. 
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Figure 3: Substrate Kinetic Determination. The Km range obtained for CS-31(02) in 
the presence of FXIIa was 0.4375 to 0.5899 mM. For subsequent measurements of FXIIa 
activity, the final concentration of CS-31(02) equaled 0.43 mM. Three independent 
experiments were performed. Each experiment consisted of three independent replicates.  
Mean ± SEM. 
 
 After establishing concentration constants for FXIIa, FXIa and CS-31(02), a 
substrate time course specification (Figure 4) was completed to quantify the ideal 
incubation period for chromogenic assays. The time course utilized the previously 
determined 9 nM FXIIa and 0.43mM CS-31(02). The assay was analyzed at increments 
of 1, 2, 4, 8, 10, 20, 30, 45, 60, 90 and 120 minuets at OD 405 nm using a BioTek 
ELx800 Absorbance Microplate Reader. The time course showed an ideal incubation 
period of 1 hour for all experiments utilizing FXIIa, FXIa, and Kallikrein.  
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Figure 4: Substrate time course. A time course using 9 nM FXIIa and 0.43 mM CS-
31(02) was used to determine the ideal incubation time for the following experiments. 
Based on this result, an incubation time of 1 hour was used for all experiments utilizing 
FXIIa, FXIa, and Kallikrein. Three independent experiments in triplicate form generated 
this data. Mean ± SEM. 
 
2.2 Determination of Enzyme Inhibition: Myricitrin and Analogues  
 Myricitrin was one of the original compounds received from the University of 
Mississippi National Center for Natural Products Research. It was a part of a double-
blind study carried out previously by the Madar’s laboratory. Once the compound was 
shown to have inhibitory effects on activated FXII, its identity was disclosed. For the 
current study, myricitrin and its various analogues were purchased commercially in order 
to perform further experimentation.  
 Myricitrin’s IUPAC name is 5,7-dihydroxy-3-[(2S,3R,4R,5R,6S)-3,4,5-
trihydroxy-6-methyloxan-2-yl]oxy-2-(3,4,5 trihydroxyphenyl)chromen-4-one and has a 
molar mass of 464.37 g/mol. Three independent chromogenic assays were completed in 
triplicate form to evaluate myricitrin’s effect on FXIIa. Findings showed that FXIIa’s 
ability to hydrolyze S2302 was effected by myricitrin. At low concentrations of the 
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compound, FXIIa showed increased activity in comparison to the control value. 
Alternatively, at a concentration of 100 M, Myricitrin showed 20-25% inhibition of 
FXIIa according to mean SEM calculations (Figure 5). This confirmed the results of 
previous studies, but was not the most successful and specific inhibitor of the desired 
protease.  
 For all of the following data representations of concentration dependent 
experiments on KKS proteases, there was a control used for each protease (FXIIa, FXIa, 
and kallikrein). Its value was used as a baseline comparison at 100% activity for the 
effectiveness of inhibitory molecules.  
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Figure 5: Determination of enzyme inhibition by Myricitrin. This compound was 
previously tested to show FXIIa inhibition. Three independent experiments were 
performed at different times. Each experiment consisted of three independent replicates.  
Mean ± SEM. 
 
 The most promising analogue of myricitrin was myricetin. It is a derivative of 
myrictrin but lacks an attached saccharide. Myricetin’s IUPAC name is 3,5,7-
Trihydroxy-2-(3,4,5-trihydroxyphenyl)-4-chromenone and has a molar mass of 318.23 
g/mol. Four independent chromogenic assays were used to test the compounds effect on 
FXIIa. Results indicated that as the concentration of myricetin increased (1 M –       
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1000 M), the inhibitory effects of the compound increased. At a concentration of     
1000 M, FXIIa was only able to hydrolyze 30% of the substrate in comparison to the 
controlled S2302 condition, absent of the protease. In conclusion, this data offered 
favorable inhibitory effects on FXIIa as seen in Figure 6.  
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Figure 6: Determination of enzyme inhibition by Myricetin. FXIIa activity was 
reduced significantly by myricetin. Four independent experiments were performed at 
different times. Each experiment consisted of three independent replicates. Mean ± SEM. 
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Next, myricetin was tested for FXIIa specificity using other proteases from the 
KKS: FXIa and Kalllikrein. Three independent assays showed that myricetin has 
inhibitory effects on FXIa. A 300 M concentration of myricetin blocked 9.56 M FXIa 
at a rate of 70-75% (Figure 7), surpassing its rate of inhibition for FXIIa. Additionally, 
myricetin blocked Kallikrein activity by 70-80% at a concentration of 30M (Figure 8). 
Overall, myricetin showed favorable inhibition of multiple proteases within the KKS.  
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Figure 7: Determination of FXIa inhibition by Myricetin. Three independent 
experiments were performed at different times. Each experiment consisted of three 
independent replicates. Mean ± SEM. 
 
In this study, there was a rise in FXIa activity at a myricetin concentration of 
1mM. This does not follow the pattern of the rest of the study. This difference was likely 
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due to an inconsistency during the dilution phase of the protocol when approaching a 
higher concentration of myricetin.  
 
 
Figure 8: Determination of Kallikrein inhibition by Myricetin. Four independent 
experiments were performed at different times. Each experiment consisted of three 
independent replicates. Mean ± SEM. 
 
 In this study, myricetin concentrations between 100 µM and 1000 µM showed an 
inconsistency from the decreasing trend. Because the error bars show overlap with nearby 
values, this increased value was determined to be not significant in comparison to the 
overall study.  
Another myricitrin analogue tested was quercetin. It differs from myricetin by 
lacking a hydroxyl group on the 5 position of the phenyl group. Quercetin’s IUPAC name 
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is 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one and has a molar mass of 
302.23 g/mol. When analyzed in a triplicate chromogenic assay with FXIIa, quercetin 
reduced FXIIa’s ability to hydrolyze S2302 down 30-40% in comparison to the S2302 
control group, according to mean SEM data calculations using Graph Pad Software. 
Because the compound’s inhibitory rate was relatively insignificant on FXIIa, further 
experiments to analyze its specificity to other proteases in the KKS were not preformed.  
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Figure 9: Determination of enzyme inhibition by Quercetin. Quercetin showed minor 
inhibition of FXII. Three independent experiments were performed at different times. 
Each experiment consisted of three independent replicates. Mean ±SEM.  
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 In this set of experiments, there was an inconsistency in the pattern of inhibition 
as the quercetin concentration reached 1 mM. This was considered to be a molar 
anomaly. Anomalous behavior has been seen in many drug-protein binding experiments 
due to complexities with bio-macromolecules and data interpretation29. Further 
experiments should be done to determine if quercetin is truly an enhancing molecule for 
FXIIa. 
Kampferol, another analogue of myricitrin, was tested for its effect on active 
FXII. It differs from myricetin by lacking a hydroxyl on the 3 and 5 position of the 
phenyl group. Kaempferol’s IUPAC name is 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-
chromen-4-one and has a molar mass of 236.23 g/mol. Three independent assays each in 
triplicate form were preformed to determine kaempferol’s effect on FXIIa. A 
concentration of 1 mM showed the most inhibitory effects on FXIIa, but it was still 
marginal (20% inhibition) in comparison to other tested compounds that were in lower 
concentrations. Because the compound did not significantly inhibit FXIIa, it was not 
analyzed with other proteases within the KKS.  
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Figure 10: Determination of enzyme inhibition by Kaempferol. Kaempferol showed 
minor inhibition of FXIIa. Kaempferol is a derivative of myricitrin. Three independent 
experiments were performed on different days. Each experiment consisted of three 
independent replicates. Mean ± SEM.  
 
 
2.3 Determination of Enzyme Inhibition: Griseofulvin  
 Like myricitrin, griseofulvin was one of the 196 double-blinded natural product 
compounds acquired from the University of Mississippi National Center for Natural 
Products Research. Following Ms. Bensel’s identification of griseofulvin as a FXIIa 
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inhibitor, I worked in conjunction with Chase Suiter to develop and execute further 
experiments with this compound. This data has been presented by Mr. Suiter at the 
Ronald E. McNair Post Baccalaureate Program in Baltimore, MD, USA in 2016. 
Additionally, I displayed our findings at the University of Mississippi Pharmacy School 
Poster Presentation in August 2016.  
 Griseofulvin’s IUPAC name is (2S,6'R)- 7-chloro- 2',4,6-trimethoxy- 6'-methyl- 
3H,4'H-spiro [1-benzofuran- 2,1'-cyclohex[2]ene]- 3,4'-dione and has a molar mass of 
352.76 g/mol. The compound’s structure differs significantly from the myricitrin 
analogues. Figure 11 demonstrates griseofulvin’s effect on 9 nM FXIIa’s ability to 
hydrolyze S2302. Concentrations of griseofulvin ranging from 1 M to 3 mM were tested 
on activated FXII using three independent chromogenic assays in triplicate form. 
Analysis showed that the IC50 for the compound is 607.0-1192 M. This data was based 
on mean SEM calculations preformed using GraphPad Prism software. At a 
concentration of 1000 M, griseofulvin inhibited FXIIa by 60% in comparison to the 
control group.  
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Figure 11: Determination of FXIIa inhibition by Griseofulvin. This compound was 
previously tested to show FXIIa inhibition. Three independent experiments were 
performed on different days. Each experiment consisted of three independent replicates. 
Mean ± SEM.  
 
Because griseofulvin was confirmed to be a promising inhibitor of FXIIa, its 
specificity was tested on other proteases in the KKS. The IC50 for griseofulvin in the 
presence of FXIa was 2.886 µM (Figure 12). The compound inhibited FXIa activity at a 
slightly lower rate than it did FXIIa. Griseofulvin was also tested in the presence of 
Kallikrein, and it did not show inhibition. To confirm that the Kallikrein used in Figure 
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12 had not lost its biological activity, Kallikrein was incubated with Kallistop, a well 
know synthetic inhibitor of Kallikrein. Concentrations of Kallistop ranged from 0.1 µM 
to 300 µM, with the 300 µM Kallistop showing ~3% Kallikrein activity. This finding 
confirmed that compound G1 does not inhibit Kallikrein (Figure 13). Overall, 
griseofulvin inhibited FXIIa and FXIa with little effect on Kallikrein (Figure 14). In 
comparison to myricetin, griseofulvin was not shown to inhibit FXIIa at a comparable 
rate.  
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Figure 12: Determination of FXIa inhibition by Griseofulvin. This compound showed 
inhibition of FXIa. One independent experiment was performed. It consisted of three 
independent replicates. Mean ± SEM. 
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Figure 13: Determination of Kallikrein inhibition by Griseofulvin. This compound 
did not show inhibition of Kallikrein, especially in comparison to its known inhibitor 
Kallistop. Three independent experiments were performed at different times. Each 
experiment consisted of three independent replicates. Mean ± SEM. 
 
Figure 14: Comparison of Griseofulvin specificity to FXIIa, FXIa and Kallikrein. 
This figure combines independent experiments with FXIa, FXIIa, and Kallikrein to 
properly compare their effects. Mean ±SEM. 
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2.4 Determination of Enzyme Inhibition in Human Plasma  
All previous experiments were performed in a pure system. The objective of 
subsequent experiments was  to determine if the same inhibitory effects could be 
duplicated in  plasma. To mimic human physiological conditions, FXIIa hydrolysis of its 
specific substrate, CS-31(02), was measured in the presence of human plasma. Human 
plasma serves as the main medium in which plasma proteins function. Figure 15 shows 
the results of a chromogenic triplicate assay with FXIIa concentrations ranging from 
0.001 nM to 2 nM. The activity of the protease grows proportionality with increasing 
concentration according to measurements taken at OD 405 nm. Data are presented as 
mean SEM.  
 
 
 
 
  
 
 
 
 
 
Figure 15: Analysis of increasing concentrations of FXIIa in human plasma. One 
independent study was used for this data. Each experiment consisted of three independent 
replicates. Mean ±SEM. 
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 Next, the inhibitory compounds were evaluated in conjunction with the KKS 
proteases in the presence of human plasma. Figure 16 depicts the findings for 
griseofulvin’s effect on FXIIa.  As a control group, a known inhibitor Kallistop (KS) was 
used as a comparative control. Kallistop reduced FXIIa’s ability to hydrolyze S2302 
shown by the second bar. In the presence of normal human plasma (NP), KS was also 
able to significantly inhibit the activity of FXIIa. Alternatively, the addition of 
griseofulvin (Gris) to the system caused an increase to active FXII’s rate of hydrolysis. In 
conclusion, this did not mimic griseofulvin’s effect on FXIIa in a pure system.  
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Figure 16: Inhibition of FXIIa in human plasma by Griseofulvin. Three independent 
experiments were performed at different times. Each experiment consisted of three 
independent replicates. Mean ± SEM. 
  
 The effect of myricitrin was then tested on KKS proteases in the presence of 
human plasma. For this characterization in plasma, FXII was intentionally activated in 
order to properly evaluate the compound in the presence of FXII. Because FXII circulates 
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in its zymogen form,  the addition of FXIIa was essential in order to draw accurate 
conclusions about FXII’s activity. Figure 17 shows the effect of myricitrin (Myr) on 
kallikrein using the known inhibitor KS as a control. In an isolated system myricitrin 
reduced the activity of kallikrein. Alternatively, in the presence of NP, myricitrin 
stimulated the activity of kallikrein. Overall, myricitrin did not show specificity to 
kallikrein in the presence of human plasma.  
 
 Inhibition of Kallikrein in Plasma by Myricitrin
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Figure 17: Inhibition of Kallikrein in human plasma by myricitrin. Three 
independent experiments were performed at different times. Each experiment consisted 
of three independent replicates. Mean ± SEM. 
 
 Further experimentation should be performed to evaluate myricetin’s effect on 
FXIIa, FXIa, and Kallikrein in a system with human plasma. The results of the 
compound’s effect on the KKS proteases are promising in a pure system. Ideally, 
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myricetin would perform the same inhibitory actions in an environment mimicking 
human physiological conditions.  
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CONCLUSION 
 This study evaluated the effects of natural product compounds on FXIIa and other 
Kallinkrein Kinin-System proteases. The findings indicated promising drug development 
opportunities. Myricetin showed the strongest inhibitory effects and specificity towards 
FXIIa. Griseofulvin and myricitrin also prevented FXIIa’s ability to hydrolyze S2303 but 
at a lesser rate. Finally, myricitrin’s analogues quercetin and kaempferol had little to no 
effect on FXIIa activity. These findings in both a pure system and in plasma offer an 
attractive target specifically blocking FXIIa. Myricetin has the potential to be a useful 
multifunctional therapeutic drug in patients with Hereditary Angioedema and 
thrombolytic diseases.  
 Finding a specific activated FXII inhibitor presents the possibility to combat a 
variety of severe health conditions including Hereditary Angioedema and thrombolytic 
diseases. Pathogenic thrombosis stemming from the plasma coagulation system has the 
capability to be effectively combated through drug targets for FXII dependent 
mechanisms. Potentially, this could impair FXII dependent fibrin formation without the 
associated risk of hemorrhage. FXII is also a target for diseases associated with 
inflammation that interact with the Kallikrein Kinin-System. Hereditary Angioedema 
Type III generates excess bradykinin that produces life threatening swelling effects. 
Inhibiting activated FXII could prematurely block the binding of bradykinin to B2 
receptors and successfully reduce proinflammatory signaling. These health conditions 
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currently lack an effective inhibitory drug served as the basis for this study. Myricetin 
offers a comprehensive range of positive effects due to its ability to inhibit FXII.  
 Further experiments are required in the field of computational biology in order to 
properly asses and explore the interaction of myricetin with crystals of FXIIa. Compound 
selectivity is the foundation of a true protease inhibitor. The chemical structure of 
myricetin offers insight into what specifically inhibits the binding region of activated 
FXII. An evaluation of this crystal structure would permit an in-depth study into the 
relationship of FXIIa and the inhibitor.  
 Current conditions affected by FXII lack specific and potent drug targets. There is 
weakness in the field of known anticoagulants due to their association with increased 
bleeding risks. A FXII inhibitor could be an effective anticoagulation drug without 
affecting hemostasis. Additionally, Hereditary Angioedema Type III lacks a specific 
inhibitor. The results of this study offer a hopeful method to combat HAE Type III, 
which currently has no established drug market. This study shows that myricetin offers 
promising opportunities for therapeutic significance in health conditions associated with 
over-activation of the Kallikrein Kinin-System.  
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EXPERIMENTAL DESIGN AND METHODOLOGY 
Background  
 This study is an expansion of experiments designed and executed by Alexandra 
Bensel (Identification of Inhibitors of Factor XII, May 2016) under the direction of Dr. 
Ziaeddin Shariat-Madar. Her focus was on Bradykinin’s role in Type III Hereditary 
Angioedema. The goal of the study was to identify potential inhibitors of FXII in order to 
reduce FXII expression and bradykinin production. Ideally, this would alleviate severe 
symptoms of Type III HAE. She tested 176 double blinded natural product molecules in 
attempt to identify inhibitors. My studies focus on two of the natural products later 
identified that showed significant inhibition of FXII in vitro.  
 
Materials 
 The Madar lab received two 96 well plates from The University of Mississippi 
National Center for Natural Products Research. The plate identifications were NCNPR-
XTL-036 and NCNPR-XTL-O47. Each plate contained samples from 88 molecules and 
all were tested in conjunction with FXII. Human Factor alpha-XIIa, Human Factor alpha-
Xia, and Plasma Kallikrein were purchased from Enzyme Research Laboratories, South 
Bend, IN, USA. The Human Factor alpha-XIIa stock concentration was 1.29 mg/ml with 
activity of 73.57 PEU/mg. To activate the Human Factor alpha-XIIa from its 
homogenous form, Dextran Sulfate was used and then taken out following activation. The 
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effect of the inhibitory compounds on FXIIa and Kallikrein were determined using the 
chromogenic substrate S-2303, also refered to as CS-31(02). It was purchased in a 4 mM 
concentration from Aniara Diagnostica, West Chester, OH, USA. For experiments 
dealing with compound specificity to FXIa, S-2366 (Glu-Pro-Arg-p-nitroanalide) was 
used as the substrate. It was purchased in a 4 mM concentration from DiaPharma Group, 
Inc. Inhibitory compounds griseofulvin and myricitrin analogues were purchased from 
Sigma-Aldrich (St. Louis, MO, USA). The plasma proteins were incubated with their 
respective enzymes in the presence of inhibitory compounds and HEPES-NaHCO3 buffer. 
The buffer solution was made in the lab using 137 mM NaCl, 3 mM KCl, 12 mM 
NaHCO3, 14.7 mM HEPES, 5.5 mM glucose, 0.1% gelatin, 2 mM CaCl2, and 1 mM 
MgCl2. The pH was then adjusted to 7.1 using HCl and NaOH. Following incubation, the 
chromogenic FXIIa activity assay was measured as change in absorbance at OD 405 nm 
using BioTek ELx800 Absorbance Microplate Reader (Winooski, VT, USA). Data were 
analyzed using GraphPad Prism software (GraphPad Software, Inc., La Jolla, CA, USA). 
 
Methods Overview 
 The effect of griseofulvin and myrcetin, new inhibitors of plasma enzymes, were 
characterized by chromogenic assay in the presence of FXIIa, FXIa, and kallikrein. 
Enzymes and peptides were always put on ice. Leaving them at room temperature could 
result in premature activation. Additionally, all pipet tips were autoclaved before use. In 
these experiments, 9 nM FXIIa was incubated with known chromogenic substrate S-2302 
that is selective for FXIIa. S-2302 is hydrolyzed by FXIIa. This process cleaves a peptide 
bond between arginine and para nitroaniline (pNA), with pNA resulting in a yellow color 
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change. A darker solution indicates that more of the substrate (S2302) is being 
hydrolyzed by FXIIa. FXIa and kallikrein were measured similarly, using 0.3 mM S2366 
and 0.4 mM S-2302, respectively. Plasma proteins were incubated with their respective 
enzyme in the absence or presence of increasing concentrations of potentially inhibitory 
natural product compounds with a final volume of 330 L. The incubation parameters 
remained constant throughout all experiments at 37ºC and 1 hour. The change in 
absorbance was measured based on the production of free para-nitroaniline at OD        
405 nm. 
 
Concentration Response: FXIa and FXIIa 
 The objective for this experiment was to determine the optimum FXIa 
concentration to use for inhibition analogues. A FXIa and S2366 control was used as a 
baseline comparison for the dependent variable. The FXIa control contained only FXIa, 
HEPES buffer (pH: 7.1), and S2366. The S2366 negative control only contained HEPES 
buffer and the respective substrate. The conditions included a varying concentration of 
the FXIa (1,2,5,10,10,20 nM). HEPES buffer (pH: 7.1) was used to obtain a final volume 
of 330 L. Lastly, a constant 0.3 mM of S2366 was added to each well quickly but 
without compromising the integrity of the experiment. Following the addition of the 
substrate, the tubes were gently pipetted in and out to mix the sample. The sample was 
then transferred in 100 L increments to triplicate wells of an assay plate. The plate was 
incubated at a temperature of 37ºC for 1 hour. The change in absorbance was measured at 
OD 405 nm to determine optimum FXIa activity. Triplicate data was taken from four 
independent experiments using mean SEM.  
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 For FXIIa, an identical methodology was used with minor changes. The substrate 
specific for FXIIa is S2302, and it was used in a 0.37 mM concentration. Additionally, 
the concentrations for FXIIa were expanded to 0.01, 0.02, 1, 2, 5, and 10 nM.   
 
Dose Response: S2302 (CS-13(02)) 
 The objective of the CS-13(02) dose response was to determine the Km of the 
substrate in the presence FXIIa. A constant 9 nM FXIIa was used in the experiment. The 
concentration of S2302 varied (10,30,100,200,300,400,500,600,800,1000 M). 
Additionally, HEPES bicarbonate buffer was added to obtain a final volume of 330 L in 
each sample tube. Following the addition of the substrate, the tubes were gently pipetted 
in and out six times to mix the sample. The sample was then transferred in 100 L 
measurements to triplicate wells of an assay plate.  The plate was incubated at a 
temperature of 37ºC for 1 hour. The change in absorbance was measured at OD 405 nm 
to determine optimum FXIa concentration. Triplicate data was taken from four 
independent experiments using mean SEM.  
 
CS-13(02) Time Course  
 The objective of the CS-13(02) time course was to determine the ideal incubation 
time for the following experiments. Activated 9 nM FXII was used along with 0.43 mM 
CS-13(02) substrate. HEPES buffer (pH: 7.1) was used to obtain a final volume of       
330 L. Following the addition of the substrate, the tubes were gently pipetted in and out 
to mix the sample. The sample was then transferred in 100 L measurements to triplicate 
wells of an assay plate. The plate was put in the incubator at 37ºC for 1 hour. It was 
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removed from the incubator and analyzed at 1, 2, 4, 8, 10, 15, 20, 30, 45, 60, 90, and 120 
minuets at OD 405 nm.  
 
Inhibition of Plasma Proteases by Myricitrin and its analogues 
 The objective of this experiment was to determine the effect of myricitrin on 
FXIIa. The conditions included a varying concentration of the inhibitory compound 
(1,3,10,30,100,300,1000 uM). A set of negative controls, lacking FXIIa, of equivalent 
concentrations were used to account for the color present in myricitrin. This control 
removed the chance of obtaining false positive results from the BioTek ELx800 
Absorbance Microplate Reader. Also, FXIIa and CS-13(02) controls were used as a 
baseline comparison for the dependent variable. The FXIIa control contained only FXIIa, 
HEPES buffer (pH: 7.1), and CS-13(02). The CS-13(02) negative control only contained 
HEPES buffer and the respective substrate. A constant 0.43 mM of S2302 was added to 
each sample tube after 9 nM activated FXII. HEPES buffer (pH: 7.1) was used to obtain a 
final volume of 330 L. Following the addition of the substrate, the tubes were gently 
pipetted in and out to mix the sample. The sample was then transferred in 100 L 
measurements to triplicate wells of an assay plate. The plate was incubated at a 
temperature of 37ºC for 1 hour. The change in absorbance was measured at OD 405 nm 
to determine the rate of FXIIa inhibition by myricitrin. Triplicate data was taken from 
four independent experiments using mean SEM.  
For myricitrin’s effect on Kallikrein, an identical protocol was used and simply 
replaced FXIIa with Kallikrein. For myricitrin’s effect on FXIa, S2366 was used as the 
substrate at a final concentration of 0.3 mM, and the remaining parameters were kept 
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constant with the other plasma protease experiments. The same protocol was used for 
experiments using myricetrin and quercetin, both analogues of myricitrin. To see 
inhibition for kaempferol and quercetin, also analogues of myricitrin, concentrations for 
the compounds were expanded to 0.01,0.03,0.1,1, and 3 mM. The other variables were 
kept uniform in order to properly compare the effects of differing analogues.   
 
Inhibition of Plasma Proteases by Griseofulvin  
 The purpose of this experiment was to determine the effects of griseofulvin on 
FXIIa. 9 nM activated FXII was used along with 0.4 mM S2302. FXIIa and S2302 
controls were used as a baseline comparison for the dependent variable. The FXIIa 
control contained only FXIIa, HEPES buffer (pH: 7.1), and S2302. The S2302 negative 
control only contained HEPES buffer and the respective substrate. The concentrations of 
griseofulvin were varied at 1, 3, 10, 30, 300, 1000, and 3000 µM. HEPES bicarbonate 
buffer (pH 7.1) was added to give each mixture a final volume of 330 L. The substrate 
was added last and in a time efficient manner. Then, each tube was pipetted in and out to 
mix the solution. The sample was transferred in 100 L measurements to triplicate wells 
of an assay plate. The plate was incubated for 1 hour at 37ºC. The change in absorbance 
was measured at OD 405 nm to determine the rate of FXIIa inhibition by griseofulvin. 
Triplicate data was taken from three to four independent experiments using mean SEM.  
 
Activated FXII in Human Plasma  
 The objective of this study was to measure FXIIa activity in normal plasma. 
FXIIa and S2302 controls were used as a baseline comparison for the dependent variable. 
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The FXIIa control contained only FXIIa, HEPES buffer (pH: 7.1), and S2302. The S2302 
negative control only contained HEPES buffer and the respective substrate. HEPES 
buffer was added to each tube to obtain a final volume of 330 L. Lastly, S2302 was 
added with a final concentration of 0.3 mM. Following the addition of the substrate, the 
tubes were gently pipetted in and out to mix the sample. The sample was then transferred 
in 100 L measurements to triplicate wells of an assay plate. The plate was incubated at a 
temperature of 37ºC for 1 hour. The change in absorbance was measured at OD 405nm to 
determine FXIIa activity in normal and deficient human plasma. Triplicate data was 
taken from three to four independent experiments using mean SEM.  
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